As more and more cell and gene therapies are being developed and with the increasing number of regulatory approvals being obtained, there is an emerging and pressing need for industrial translation. Process efficiency, associated cost drivers and regulatory requirements are issues that need to be addressed before industrialisation of cell and gene therapies can be established. Automation has the potential to address these issues and pave the way towards commercialisation and mass production as it has been the case for ‘classical’ production industries. This review provides an insight into how automation can help address the manufacturing issues arising from the development of large-scale manufacturing processes for modern cell and gene ther...
The translation of experimental cell-based therapies to volume produced commercially successful clin...
The manufacturing of cell therapy is a complex sequence of different unit operations. The substantia...
Successful commercialisation of cell therapies will be underpinned by cost-effective, robust and sca...
As more and more cell and gene therapies are being developed and with the increasing number of regul...
As more and more cell and gene therapies are being developed and with the increasing number of regul...
The development of novel, affordable and efficacious therapeutics will be necessary to ensure the co...
Decentralized, or redistributed manufacture, is likely to be the manufacturing approach of choice fo...
Autologous cell therapies are currently being evaluated in multiple clinical trials and are becoming...
The rapidly growing field of cell therapy is providing very promising treatments for conditions that...
As the field of cell and gene therapy continues to progress, the need for cell products for therapeu...
Phacilitate held a Special Interest Group workshop event in Edinburgh, UK, in May 2017. The event br...
Allogeneic cell therapy products are generating encouraging clinical and pre-clinical results. Pluri...
BACKGROUND. A novel manufacturing industry is emerging to translate unique cellular therapy bioproce...
The development of novel, affordable and efficacious therapeutics will be necessary to ensure the co...
Designing manufacturing processes to reproducibly generate process-sensitive human cells of sufficie...
The translation of experimental cell-based therapies to volume produced commercially successful clin...
The manufacturing of cell therapy is a complex sequence of different unit operations. The substantia...
Successful commercialisation of cell therapies will be underpinned by cost-effective, robust and sca...
As more and more cell and gene therapies are being developed and with the increasing number of regul...
As more and more cell and gene therapies are being developed and with the increasing number of regul...
The development of novel, affordable and efficacious therapeutics will be necessary to ensure the co...
Decentralized, or redistributed manufacture, is likely to be the manufacturing approach of choice fo...
Autologous cell therapies are currently being evaluated in multiple clinical trials and are becoming...
The rapidly growing field of cell therapy is providing very promising treatments for conditions that...
As the field of cell and gene therapy continues to progress, the need for cell products for therapeu...
Phacilitate held a Special Interest Group workshop event in Edinburgh, UK, in May 2017. The event br...
Allogeneic cell therapy products are generating encouraging clinical and pre-clinical results. Pluri...
BACKGROUND. A novel manufacturing industry is emerging to translate unique cellular therapy bioproce...
The development of novel, affordable and efficacious therapeutics will be necessary to ensure the co...
Designing manufacturing processes to reproducibly generate process-sensitive human cells of sufficie...
The translation of experimental cell-based therapies to volume produced commercially successful clin...
The manufacturing of cell therapy is a complex sequence of different unit operations. The substantia...
Successful commercialisation of cell therapies will be underpinned by cost-effective, robust and sca...